HK Stock Market Move | SUNSHINE PHARMA (06887) is up nearly 6% with approval for clinical trial of siRNA therapy for hepatitis B and recent approval for generic fenofibrate hydrochloride capsules.

SUNSHINE PHARMA (06887) is now up nearly 6%, with a gain of 5.41% at the time of writing, trading at 48.28 Hong Kong dollars, with a transaction amount of 2012.9 million Hong Kong dollars. On the news front, according to public information from the National Medical Products Administration, SUNSHINE PHARMA's self-developed class 1 new drug - small interfering RNA (siRNA) therapy HECN30227 has recently been approved to conduct clinical trials for the treatment of chronic hepatitis B. This development not only brings new hope for functional cure of hepatitis B, but also signifies a critical step forward in China's research and development of small nucleic acid drugs. It is worth noting that SUNSHINE PHARMA's recently approved oral drug SUNSHINE PHARMA Fingomod hydrochloride capsules for the treatment of multiple sclerosis (MS) is the first domestically produced drug for this indication. Fingomod has performed well in the global market, with sales exceeding $3.3 billion in 2018 and expected to surpass $5 billion by 2024. SUNSHINE PHARMA initiated this project in 2011, filed applications in multiple countries, became the first to apply for generic approval in China in 2020, and recently received approval, breaking the monopoly of the original drug. Currently, only products related to Dr. Reddy's Laboratories in India are at the evaluation and approval stage.